NCT00476827: A Phase II Safety and Tolerability Study of Bevacizumab When Added to Single-agent Chemotherapy to Treat Patient With Breast Cancer Metastatic to Brain |
|
|
| Terminated | 2 | 16 | US | Bevacizumab, Avastin, Docetaxel, Taxotere, CPT-11, Irinotecan, Camptosar, Paclitaxel, Taxol, Vinorelbine Tartrate, Navelbine®, Gemcitabine, difluorodeoxycytidine | Duke University, Genentech, Inc. | Breast Cancer | 05/11 | 05/11 | | |
